Published in Blood on January 08, 2008
Rho1 regulates apoptosis via activation of the JNK signaling pathway at the plasma membrane. J Cell Biol (2010) 1.16
Characterization of the Ca2+ -regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem (2008) 0.92
Ezrin dephosphorylation/downregulation contributes to ursolic acid-mediated cell death in human leukemia cells. Blood Cancer J (2013) 0.91
Spatial coupling of JNK activation to the B cell antigen receptor by tyrosine-phosphorylated ezrin. J Immunol (2013) 0.89
Sphingolipid regulation of ezrin, radixin, and moesin proteins family: implications for cell dynamics. Biochim Biophys Acta (2013) 0.85
Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia (2015) 0.83
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 7.00
Protein interaction mapping: a Drosophila case study. Genome Res (2005) 4.15
Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol (2004) 3.03
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 2.38
Overview of the matrisome--an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol (2012) 2.26
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene (2002) 1.87
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta (2006) 1.80
The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res (2005) 1.76
Molecular analysis of microscopic ezrin dynamics by two-photon FRAP. Proc Natl Acad Sci U S A (2002) 1.73
Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell (2003) 1.67
ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol (2002) 1.61
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood (2004) 1.60
PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep (2012) 1.58
Emerging role for ERM proteins in cell adhesion and migration. Cell Adh Migr (2011) 1.58
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency? Br J Haematol (2011) 1.55
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica (2006) 1.54
A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem (2002) 1.49
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res (2010) 1.46
Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood (2002) 1.43
Ezrin tunes T-cell activation by controlling Dlg1 and microtubule positioning at the immunological synapse. EMBO J (2010) 1.40
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood (2010) 1.38
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood (2002) 1.37
Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42. Mol Biol Cell (2007) 1.36
The NHE3 juxtamembrane cytoplasmic domain directly binds ezrin: dual role in NHE3 trafficking and mobility in the brush border. Mol Biol Cell (2006) 1.34
Delocalization of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones: exclusion from the nucleus and accumulation in dendritic granules and spine heads. Neurosci Lett (2005) 1.26
beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood (2007) 1.25
Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood (2010) 1.23
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica (2009) 1.21
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood (2005) 1.20
Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics (2009) 1.14
Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol (2005) 1.14
Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica (2011) 1.13
Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery? Curr Cancer Drug Targets (2003) 1.12
Interaction of ezrin with the novel guanine nucleotide exchange factor PLEKHG6 promotes RhoG-dependent apical cytoskeleton rearrangements in epithelial cells. Mol Biol Cell (2007) 1.12
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood (2002) 1.12
Structural plasticity of perisynaptic astrocyte processes involves ezrin and metabotropic glutamate receptors. Proc Natl Acad Sci U S A (2011) 1.12
Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med (2011) 1.09
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle (2011) 1.09
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica (2011) 1.07
Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J (2003) 1.07
IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood (2010) 1.03
Co-operative effect of c-Src and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells. J Cell Biochem (2004) 1.03
The ERM proteins interact with the HOPS complex to regulate the maturation of endosomes. Mol Biol Cell (2010) 1.02
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell (2005) 1.01
Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract (2004) 1.01
Spatial recruitment and activation of the Fes kinase by ezrin promotes HGF-induced cell scattering. EMBO J (2007) 1.01
Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem (2002) 0.98
Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J (2010) 0.98
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood (2011) 0.98
Towards definition of an ECM parts list: an advance on GO categories. Matrix Biol (2012) 0.97
Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle (2009) 0.95
Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation. J Biol Chem (2006) 0.95
Ezrin regulates microvillus morphogenesis by promoting distinct activities of Eps8 proteins. Mol Biol Cell (2012) 0.93
Spi-1/PU.1 oncoprotein affects splicing decisions in a promoter binding-dependent manner. J Biol Chem (2006) 0.93
Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood (2005) 0.92
The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood (2012) 0.92
Ezrin phosphorylation on tyrosine 477 regulates invasion and metastasis of breast cancer cells. BMC Cancer (2012) 0.92
Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells. Mol Cell Biol (2009) 0.90
Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. Cancer Res (2010) 0.90
Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach. Proteomics (2008) 0.89
p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica (2010) 0.88
Involvement of the Src kinase Lyn in phospholipase C-gamma 2 phosphorylation and phosphatidylinositol 3-kinase activation in Epo signalling. Biochem Biophys Res Commun (2003) 0.87
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. Blood (2012) 0.86
Moesin/ezrin: a specific role in cell metastasis? Pigment Cell Melanoma Res (2009) 0.85
High-mobility group protein HMGB2 regulates human erythroid differentiation through trans-activation of GFI1B transcription. Blood (2009) 0.85
Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One (2013) 0.85
Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia. Nucleic Acids Res (2012) 0.85
Mass spectrometry detection of G3m and IGHG3 alleles and follow-up of differential mother and neonate IgG3. PLoS One (2012) 0.84
Isolation and characterization of an aggresome determinant in the NF2 tumor suppressor. J Biol Chem (2002) 0.84
Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation. Blood (2007) 0.84
PU.1/Spi-1 binds to the human TAL-1 silencer to mediate its activity. J Mol Biol (2005) 0.83
Ezrin ubiquitylation by the E3 ubiquitin ligase, WWP1, and consequent regulation of hepatocyte growth factor receptor activity. PLoS One (2012) 0.83
From mice to human: the "two-hit model" of leukemogenesis. Cell Cycle (2006) 0.81
Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase. PLoS One (2009) 0.81
Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i )protein beta gamma-subunit-initiated pathway. J Biol Chem (2003) 0.81
Characterization of cytosolic proliferating cell nuclear antigen (PCNA) in neutrophils: antiapoptotic role of the monomer. J Leukoc Biol (2013) 0.80
Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. Oncogene (2004) 0.80
Spi-1/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythroleukemia cells. Oncogene (2004) 0.80
The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. Br J Haematol (2011) 0.80
Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes. Mol Cancer Res (2013) 0.79
Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity. Int J Oncol (2009) 0.78
Ezrin/radixin/moesin are required for the purinergic P2X7 receptor (P2X7R)-dependent processing of the amyloid precursor protein. J Biol Chem (2012) 0.78
Insulin receptor A and IGF-1R in AML - Letter. Cancer Res (2010) 0.77
New variant of unclassified congenital dyserythropoietic anaemia: the concept of the erythroid regulator? Br J Haematol (2011) 0.77
Phosphatidylinositol 3-kinase regulates glycosylphosphatidylinositol hydrolysis through PLC-gamma(2) activation in erythropoietin-stimulated cells. Cell Signal (2002) 0.77